Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Report 2026

Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Overview

• Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits market size has reached to $1.05 billion in 2025 • Expected to grow to $1.99 billion in 2030 at a compound annual growth rate (CAGR) of 13.5% • Growth Driver: Rising Incidence Of Prostate Cancer Fueling The Growth Of The Market Due To Aging Population And Increasing Disease Burden • Market Trend: Advanced Diagnostic Kits Support Targeted Therapy And Treatment Planning • North America was the largest region in 2025.

What Is Covered Under Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

Prostate-specific membrane antigen (PSMA) theranostic kits are specialized tools for the detection and treatment of prostate cancer by targeting the PSMA protein highly expressed on cancer cells. They combine a PSMA-targeted imaging agent for accurate tumor localization with a therapeutic component that delivers treatment directly to cancer cells. These kits enable personalized medicine by improving cancer staging, monitoring treatment response, and minimizing damage to healthy tissue. The main product types of prostate-specific membrane antigen (PSMA) theranostic kits are diagnostic kits, therapeutic kits, and combined theranostic kits. Diagnostic kits are tools that detect and visualize PSMA-expressing cancer cells using imaging agents, enabling accurate tumor localization, staging, and monitoring of prostate cancer. These find applications in prostate cancer, and others, serving end-users such as hospitals, diagnostic centers, research institutes, specialty clinics, and others.

What Is The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Growth Forecast?

The prostate-specific membrane antigen (psma) theranostic kits market size is expected to see rapid growth in the next few years. It will grow to $1.99 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to increasing demand for personalized cancer treatments, rising investments in theranostics, expansion of nuclear medicine infrastructure, growing use of precision oncology diagnostics, increasing regulatory approvals for targeted therapies. Major trends in the forecast period include increasing adoption of targeted radioligand therapies, rising use of psma-based precision diagnostics, growing integration of imaging and therapy workflows, expansion of personalized oncology treatment kits, enhanced focus on companion diagnostics.

Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Segmentation

1) By Product Type: Diagnostic Kits, Therapeutic Kits, Combined Theranostic Kits 2) By Application: Prostate Cancer, Other Cancers 3) By End-User: Hospitals, Diagnostic Centers, Research Institutes, Specialty Clinics, Other End-Users Subsegments: 1) By Diagnostic Kits: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography Imaging Kits, Single Photon Emission Computed Tomography Imaging Kits, Companion Diagnostic Kits, Liquid Biopsy Kits 2) By Therapeutic Kits: Radioligand Therapy Kits, Antibody-Based Therapy Kits, Peptide-Based Therapy Kits, Small Molecule Therapy Kits 3) By Combined Theranostic Kits: Integrated Imaging And Therapy Kits, Dual Function Radiopharmaceutical Kits, Prostate-Specific Membrane Antigen (PSMA) Ligand-Based Theranostic Kits, Personalized Treatment Kits

What Is The Driver Of The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

The rising incidence of prostate cancer is expected to propel the growth of the prostate-specific membrane antigen (PSMA) theranostic kits market going forward. Prostate cancer refers to a type of cancer that develops in the prostate gland, a small gland in men located below the bladder and in front of the rectum. The rising prevalence of prostate cancer is due to the aging population, as the risk of developing prostate cancer increases significantly with age. Prostate-specific membrane antigen (PSMA) theranostic kits enhance prostate cancer management by offering targeted diagnostic solutions, making them ideal for early detection and personalized treatment planning. They improve diagnostic accuracy by combining PSMA-specific ligands with radiotracers, supporting better disease monitoring and therapy guidance. For instance, in November 2023, according to the American Cancer Society, a US-based non-profit organization, approximately 313,780 new cases of prostate cancer and 35,770 deaths were estimated in the United States in 2025. Therefore, the rising incidence of prostate cancer is driving the growth of the prostate-specific membrane antigen (PSMA) theranostic kits industry.

Key Players In The Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

Major companies operating in the prostate-specific membrane antigen (psma) theranostic kits market are Cyclotek (Aust) Pty Ltd, Telix Pharmaceuticals Ltd, Curium Pharma, SOFIE Biosciences Inc., Lantheus Holdings Inc., Eckert & Ziegler SE, NorthStar Medical Radioisotopes, Isotopia Molecular Imaging Ltd, ITM Isotope Technologies Munich SE, AdvanCell Pty Ltd, Alpha‑9 Theranostics Inc., ABX Advanced Biochemical Compounds GmbH, Clarity Pharmaceuticals Ltd, Ariceum Therapeutics GmbH, RadioMedix Inc., Scintomics GmbH, Novartis AG, Bayer AG, POINT Biopharma Inc., Blue Earth Diagnostics

Global Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Trends and Insights

Major companies operating in the prostate-specific membrane antigen (PSMA) theranostic kits market are focusing on developing innovative solutions, such as PSMA-targeted radioligand kits, to meet the rising demand for precision oncology, targeted prostate cancer diagnosis, and therapy. PSMA-targeted radioligand kits are medical kits that combine a ligand specifically designed to bind to Prostate-Specific Membrane Antigen (PSMA) with a radioactive isotope for diagnostic imaging or targeted therapy of prostate cancer. For instance, in March 2025, Telix Pharmaceuticals Limited, an Australia-based radiopharmaceutical company, launched Illuccix, an innovative kit for the preparation of Gallium-68 gozetotide injection. This kit enables hospitals and nuclear medicine facilities to label the radionuclide immediately before injection for PET imaging of PSMA-positive prostate cancer lesions. The kit’s unique features include a ready-to-use preparation format, disease-specific targeting, rapid imaging capability, and compatibility with theranostic workflows, allowing better detection of metastatic lesions, treatment planning, and monitoring therapy response. Its applications include the diagnosis of recurrent or metastatic prostate cancer and guiding personalized treatment decisions, making it a significant advancement over conventional imaging or non-targeted therapies.

What Are Latest Mergers And Acquisitions In The Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

In June 2023, Ariceum Therapeutics GmbH, a Germany-based biotech company, acquired Theragnostics Ltd. for an undisclosed amount. With this acquisition, Ariceum Therapeutics aims to enhance its technological capabilities in PSMA-targeted theranostic kits and expand its radiopharmaceutical portfolio in prostate cancer imaging. Theragnostics Ltd. is a UK-based biopharmaceutical company that develops PSMA-targeted diagnostic kits specifically 68Ga THP PSMA for prostate cancer imaging.

Regional Outlook

North America was the largest region in the prostate-specific membrane antigen (PSMA) theranostic kits market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market?

The prostate-specific membrane antigen (PSMA) theranostic kits market consists of sales of radiolabeled therapeutic agents, diagnostic kits, combination theranostic kits, antibody-based PSMA theranostics, PSMA ligand-based drug conjugates, and companion diagnostic kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Report 2026?

The prostate-specific membrane antigen (psma) theranostic kits market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the prostate-specific membrane antigen (psma) theranostic kits industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.